Results 281 to 288 of about 78,045 (288)

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou, Huilin Tang, Bingyu Zhang, Dazheng Zhang, Yiwen Lu, Lu Li, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Ultrasound and MRI abdominal fat distribution and its associations with metabolic conditions in adults with abdominal obesity

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the accuracy of abdominal fat distribution of subcutaneous (SAT) and visceral adipose tissue (VAT) assessed by ultrasound (US) compared to magnetic resonance imaging (MRI), as the gold standard technique. Additionally, to assess the association between abdominal fat distribution measured by US and metabolic conditions in ...
Claudia Jiménez‐ten Hoevel, Maria Besora‐Moreno, Judit Queral, Elisabet Llauradó, Rosa M. Valls, Rosa Solà, Anna Pedret   +6 more
wiley   +1 more source

Defective high‐density lipoprotein lipoprotection in type 2 diabetes during acute myocardial infarction is rescued by apolipoprotein M/sphingosine‐1‐phosphate loading

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Mortality of patients with type 2 diabetes (T2D) after acute myocardial infarction (AMI) is tremendous and massively increased compared to non‐T2D individuals. The reasons are unclear. High‐density lipoprotein (HDL) conducts lipoprotection during AMI, leading to improved outcomes.
Jens Vogt, Marcel Benkhoff, Nathalie H. Schröder, Hao Hu, Lisa Dannenberg, Petra Keul, Theresia Sarabhai, Kálmán Benedikt Bódis, Tobias Zeus, Philipp Wollnitzke, Malte Kelm, Amin Polzin, Bodo Levkau   +12 more
wiley   +1 more source

Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Imeglimin is a novel oral hypoglycemic agent approved for the treatment of type 2 diabetes in Japan, with dual actions to enhance insulin secretion and improve insulin sensitivity, suggested by preclinical evidence. However, the effect of imeglimin on tissue‐specific insulin sensitivity and glucose kinetics using glucose tracers is ...
Tsubasa Tajima, Hideyoshi Kaga, Naoaki Ito, Toshiki Kogai, Hitoshi Naito, Saori Kakehi, Satoshi Kadowaki, Yuya Nishida, Ryuzo Kawamori, Yoshifumi Tamura, Hirotaka Watada   +10 more
wiley   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Is AMP‐activated protein kinase activation a central mechanism of cardio‐metabolic outcomes after metabolic and bariatric surgery?

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity. It usually results in spectacular weight loss, associated with improvements of obesity‐associated comorbidities. The mechanisms underlying these benefits are not fully understood but could involve a postoperative activation of the enzyme 5′ AMP‐activated ...
Adrien Delcour, Nathalie Niederhoffer
wiley   +1 more source

Anti-JNK2 peptide–siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice [PDF]

, 2018
Akk, Antonina, Bacon, John, Hou, Kirk K, Miller, Mark J, Palekar, Rohun U, Pan, Hua, Pham, Christine T.N, Schlesinger, Paul H, Springer, Luke E, Wickline, Samuel A, Yan, Huimin, Yang, Lihua   +11 more
core   +1 more source

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, EarlyView.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source